<DOC>
	<DOCNO>NCT00879866</DOCNO>
	<brief_summary>Primary trial objective single arm trial ass safety tolerability Selectikine ( EMD 521873 ) give combination local tumor irradiation determine whether maximum tolerate dose ( MTD ) reach EMD 521873 dose 0.45 mg/kg . Secondary objective evaluate PK , immunogenicity , overall response , change tumor marker level circulate tumor cell number , progression-free survival overall survival . Also , evaluate biological/immune response EMD 521873 . NSCLC patient stable ( PR SD ) first-line chemotherapy order enrol . A total 12 24 patient plan . Patients remain dose throughout trial . It intend administer least 4 cycle ( 21 ) , progression 2nd line therapy become necessary .</brief_summary>
	<brief_title>EMD 521873 Plus Radiotherapy Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC stage IIIb malignant pleural effusion stage IV Pulmonary primary tumor least one NSCLC metastasis lung measure least 1 cm diameter eligible local radiation 20 Gy Disease control ( partial remission stable disease ) 4 cycle platinumbased firstline chemotherapy whereby time last dose firstline chemotherapy start trial treatment longer 8 week Male female , age ≥18 year age Signed write informed consent Effective contraception male female subject childbearing age ECOG performance status 0 1 Adequate hematological function define WBC ≥3 x 10^9/L , neutrophil ≥1.5 x 10^9/L , lymphocyte count ≥0.5 x 10^9/L , platelet count ≥100 x 10^9/L ; hemoglobin ≥9 g/dL Estimated creatinine clearance ≥50 mL/min accord Cockcroft Gault formula 24h urine sample Adequate hepatic function define total bilirubin level ≤1.5 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤5 x ULN Requirement immunosuppressive treatment exception inhalative corticosteroid lowdose systemic corticosteroid ( prednisone equivalent dose ≤10 mg/day ) Systemic autoimmune disease ( e.g . lupus erythematodes , rheumatoid arthritis ) Organ transplant recipient Active infection ( include HIV , hepatitis B C , tuberculosis ) Known clinically suspect brain metastasis Active cardiovascular/cerebrovascular disease ( e.g . symptomatic coronary vascular disease , congestive heart failure ≥ NYHA II , LVEF &lt; 50 % , ventricular arrhythmia require medication , myocardial infarction stroke ) within previous 6 month Pericardial effusion Major impairment pulmonary function : forced expir¬atory volume 1 second ( FEV1 ) &lt; 50 % diffusion capacity carbon monoxide ( DLCO ) &lt; 50 % normal limit Any significant disease Investigator 's opinion would exclude subject trial Known condition associate necroses nontumor bearing tissue ( e.g . esophageal gastroduodenal ulcer , ischemic bowel disease , chronic inflammation ) Pregnancy lactation Radiotherapy , chemotherapy , major surgery , biological therapy investigational drug within 30 day prior start trial treatment Requirement concurrent systemic anticancer treatment ( chemotherapy , biological therapy ) Pretreatment antiEGFR antibody tyrosine kinase inhibitor Participation another interventional clinical trial within past 30 day start trial treatment Known alcohol drug abuse Any psychiatric condition would prohibit understanding rendering informed consent Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>immunocytokine</keyword>
	<keyword>radiation</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>maintenance therapy</keyword>
</DOC>